Harrow, Inc. Accrued Liabilities, Current
Harrow, Inc. (HROW) had Accrued Liabilities, Current of $59.00 thousand as of 2023-09-30, per its 10-Q filed 2023-11-13.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2023-11-13
- 2023-09-30: Accrued Liabilities, Current $59.00K.
- 2017-09-30: Accrued Liabilities, Current $251.00K.
- 2014-09-30: Accrued Liabilities, Current $38.17K.
| Period end | Accrued Liabilities, Current |
|---|---|
| 2023-09-30 | $59.00K 10-Q · filed 2023-11-13 |
| 2017-09-30 | $251.00K 10-Q · filed 2017-11-14 |
| 2014-09-30 | $38.17K 10-Q · filed 2014-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |